Anebulo Pharmaceuticals Inc
Research Anebulo Pharmaceuticals Inc (ANEB) on Bullrun: market cap USD 13.46M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerANEB
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 13.46M
- Financial periodFY2025
- RevenueUSD 0
- Net income-USD 8.48M
- Free cash flow-USD 5.84M
Valuation Snapshot
latest market cap is USD 13.46M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 8.48M | -USD 5.84M | n/a | -0.25 | USD 11.63M | n/a | USD 11.66M |
| FY2024 | USD 0 | -USD 8.20M | -USD 6.65M | n/a | -0.32 | USD 3.09M | n/a | USD 3.81M |
| FY2023 | n/a | -USD 11.73M | n/a | n/a | -0.47 | USD 11.25M | n/a | USD 10.60M |
| FY2022 | n/a | -USD 6.83M | n/a | n/a | 0.29 | USD 14.55M | n/a | USD 15.07M |
| FY2021 | n/a | -USD 30.25M | n/a | n/a | n/a | USD 19.99M | n/a | USD 21.41M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 13.46M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 41.50M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 69.02M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 62.03M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 62.03M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 143.57M | n/a | n/a | n/a |
About Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Anebulo Pharmaceuticals Inc's market cap?
Anebulo Pharmaceuticals Inc's market capitalization is USD 13.46M.
What does Anebulo Pharmaceuticals Inc do?
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.